37, p = 0.020), and baseline ALT > 45 for males and > 30 for females (HR 2.26, p < 0.0001) were significant predictors of treatment initiation, but not practice setting. Similarly,

only older age (HR 1.02, p < 0.0001), male gender (HR 1.42, p = 0.019) and baseline ALT > 45 for males and > 30 for females (HR 2.81, p < 0.0001) were significant independent predictors of starting treatment within the first year of treatment eligibility and not practice setting. Conclusion: The majority of patients who started treatment started within one year of becoming treatment eligible; however, approximately 40% of patients still have not started treatment on longer follow-up. Further studies are needed to determine the barriers for treatment initiation in diverse practice settings. Disclosures: Huy N. Trinh - Advisory Committees or Review Panels: BMS, Gilead; Grant/ Research Support: selleck chemicals llc BMS, Gilead; Speaking and Teaching: BMS, Gilead, vertex; Stock Shareholder: Gilead Huy A. Nguyen – Advisory Committees or Review Panels: Gilead, BMS; Speaking and Teaching: Gilead Mindie H. Nguyen – Advisory Committees or Review Panels: Bristol-Myers Squibb, Bayer AG, Gilead, Novartis, Onyx; Consulting: Gilead Sciences, Inc.; Grant/Research Support: Gilead Sciences, Inc., Bristol-Myers Squibb, Novartis AZD1208 order Pharmaceuticals, Roche Pharma AG, Idenix, Hologic, ISIS The following people have nothing to disclose: Vinh

D. Vu, Ailinh Do, Nghia H. Nguyen, Lily H. Kim, Khanh Nguyen Background. Fibrosis-regression(FR) rate in treated CHB-patients patients was similary estimated using Fibrotest and LSM (Fibros-can),

although with possible overestimation of FR by LSM related to necroinflammatory activity(NIA).(AntivirTher2009,2010) Aims. To prospectively evaluate : 1)The histological impact of strong inhibitor of HBV-replication, entecavir-motherapy [0.5mg/day], using Fibrotest-Actitest and LSM.2) The impact of presumed steatosis(Steatotest) on the treatment response. Methods. NUC-naïve CHB preincluded [19-centers,France] fol-lowed-up (FU) 上海皓元 from baseline to M6,M12 and M24-months. Viral-response(VR) defined as undetectable-HBVDNA. Results. N=177 pre-included, 15-retracted, 3-died, 5 non-applicable Fibrotest (4 flare-up ALT>600IU/L), 24 lost-of-follow-up (FU); N=137 with M6-FU included [age 45(20-83)yrs; 71%males; 84% anti-HBe(+); 43%caucasian/29%asian/28%african]. Applicable-LSM vs Fibrotest 95%vs97.2%(p<0.0001). Fibro- test presumed advanced fibrosis(AF,F2F3F4-METAVIR) in 36%(60/167) and cirrhosis 12%(N=20/167); presumed NIA (Actitest) in 74%(123/166) and baseline steatosis>1% (Steatotest) 37%(57/156). N=43 had liver biospy [size 24(5-40)] AF 56%(24/43). VR prevalences were 67% M6(N=120), 83% M12(N=105) and 86%M24(N=50). Presumed NIA [Actitest] regressed from M0 0.38(0.02) to M6 0.21(0.01), M12 0.19(0.01) and M24 0.14(0.02), all p<0.0001vsM0. 76% patients with baseline-NIA regressed at M6. Presumed AF [Fibrotest] regressed from M0 0.69(0.02) vs M6 0.59(0.03) vs M12 0.57(0.03), M24 0.